8 stars: A look back at AS­CO spot­lights the top can­cer drugs to watch, and 1 to for­get

I’ve been mak­ing the trek to AS­CO for some years now, and I don’t re­call any oth­er week that ri­vals what I’ve just seen. There wasn’t just im­por­tant da­ta to re­port on, there was a lot of it.

CAR-T, with all of its splen­did ini­tial promise in liq­uid tu­mors, is reach­ing the first ma­jor com­mer­cial fin­ish line, with No­var­tis’ $NVS CTL019 out in front of Kite’s $KITE KTE-C19 by a nose. No­var­tis wait­ed to cap­ture the in­dus­try’s at­ten­tion at an­oth­er con­fer­ence mid-week with head-to-head da­ta, but you bet­ter be­lieve it fig­ured promi­nent­ly on my AS­CO in­ter­view sched­ule.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.